Seismic Pharmaceuticals Commences Global Phase 3 Trial of Istaroxime for Cardiogenic Shock
核心洞察
Seismic Pharmaceuticals (搜索) has commenced RESCUE HF-CS, a global Phase 3 trial of istaroxime in cardiogenic shock (搜索), enrolling the first patient on September 9, 2026.
The approximately 600-patient study spans sites across the United States, Europe, China, and South America, building on four completed Phase 2 trials involving more than 340 patients.
Istaroxime is a first-in-class dual-mechanism therapy that inhibits Na/K ATPase (搜索) and activates SERCA2a (搜索) to improve both systolic contraction and diastolic relaxation.
Seismic Pharmaceuticals (搜索) has commenced RESCUE HF-CS, its global Phase 3 trial of istaroxime in patients with cardiogenic shock (搜索), enrolling the first patient on September 9, 2026. The study is designed to become the first drug ever approved to treat this life-threatening condition, for which there are currently no FDA-approved treatments.
The approximately 600-patient study will be conducted at clinical sites across the United States, Europe, China, and South America. The trial builds upon four completed Phase 2 studies in which more than 340 patients received istaroxime, including a Phase 2b extension study in which cardiac output rose roughly 15% during infusion with no significant increase in heart rate.
A Persistent Unmet Need
Cardiogenic shock (搜索) is a life-threatening condition that occurs when the heart is unable to pump enough blood to meet the body's needs, resulting in inadequate blood flow and oxygen delivery to vital organs. It may occur as a complication of acute heart failure, a severe heart attack, or other serious cardiac conditions.
Despite advances in critical care and mechanical circulatory support, cardiogenic shock (搜索) continues to be associated with high rates of complications and mortality. A large prospective analysis cited in the program's background confirms an ICU mortality rate of 44.8%, underscoring how sick this population is and how little time investigators have to capture patients at the right point in their deterioration.
A Dual Mechanism of Action
Istaroxime is a novel, first-in-class therapy being developed to improve cardiac function and hemodynamic stability in patients with cardiogenic shock (搜索). Unlike conventional inotropic therapies, istaroxime has a unique dual mechanism of action designed to improve both systolic contraction and diastolic relaxation.
The drug works through two simultaneous actions: it inhibits Na/K ATPase (搜索), which increases the calcium available for each contraction, and it activates SERCA2a (搜索), the pump that clears calcium from the cell between beats. Stimulating SERCA2a accelerates calcium cycling and improves diastolic relaxation, meaning the heart refills more completely before the next beat. Most inotropes address only the squeeze; istaroxime addresses both sides of the cardiac cycle.
This distinction carries clinical significance. The inotropes physicians currently use off-label in cardiogenic shock (搜索) tend to raise myocardial oxygen demand and increase arrhythmia risk, two problems istaroxime's mechanism is designed to avoid. In the Phase 2b data, the drug also reduced ventricular arrhythmias in patients on continuous 72-hour ECG monitoring, a signal worth watching in Phase 3 where the trial is large enough to power a meaningful event count.
Trial Scale and Operational Challenges
The size of the Phase 3 program relative to the Phase 2 experience—600 patients versus more than 340 across all prior studies combined—reflects how difficult cardiogenic shock (搜索) trials are to run. Patients are critically ill, enrollment windows are narrow, and sites need intensive care infrastructure.
"The commencement of this global Phase 3 trial represents an important milestone for Seismic Pharmaceuticals (搜索) and for the development of Istaroxime," said Gad Cotter, CEO and Chairman of the Board. "Cardiogenic shock (搜索) remains a life-threatening condition with a significant need for new treatment options. This study builds upon the clinical experience generated in more than 340 patients across four Phase 2 trials, and we look forward to working with investigators and clinical sites throughout the United States, Europe and South America to advance this program."
The primary enrollment milestone to watch is whether Seismic can sustain site activation across four continents fast enough to keep the 600-patient target within a realistic timeframe.